Ampio Pharmaceuticals, Inc. (AMPE) is showing solid up movement with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company`s partner Daewoong Co., which will finance and conduct the trials. Amylin Pharmaceuticals, Inc. (AMLN) added 8.83% to $30.69 and made a new 52-week high of $30.75. This morning Bristol Myers Squibb Co.(BMY) agreed to buy the company for $5.3 billion or $31 per share in cash. Following an acquisition of Amylin, analyst at Piper Jaffray issued a positive note on various biotech stocks and stated those companies would be an acquisition target. BioMarin Pharmaceutical Inc.(BMRN) climbed 1.47 (3.71%) to $41.05, Theravance Inc(THRX) added 1.77 (7.94%) at $23.99, Affymax, Inc.(AFFY) rose 0.19 (1.48%) to $13.07 and Rigel Pharmaceuticals, Inc.(RIGL) surged 0.13 (1.40%) to $9.43. Cytori Therapeutics Inc. (CYTX) extended its uptrend and rose another 9.26% to $2.95. The stock has been showing solid buying since early July and went up all the way from $2.05 to $2.95 in about … Continue reading →

Greenwood Village, CO//PRNewswire via COMTEX/ -- Ampio Pharmaceuticals, Inc. /quotes/zigman/5133505/quotes/nls/ampe AMPE +9.84% , a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane(TM) to treat PE in the USA. Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully complements … Continue reading →

GREENWOOD VILLAGE, Colo., July 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane to treat PE in the USA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully … Continue reading →

REUTERS - Ampio Pharmaceuticals Inc (NAQ:AMPE - News) signed a deal with Syngene, a unit of Bangalore-based Biocon Ltd (NSI:BIOCON.NS - News), to produce its experimental drug for premature ejaculation and erectile dysfunction, sending its shares up 23 percent. The combination drug, Zertane-ED, would be made by Syngene, Ampio said. Ampio's Korea-based partner Daewoong Co Ltd will finance and conduct late-stage studies in South Korea. "We will be working with Daewoong to get the study approved by the U.S. Food and Drug Administration and in South Korea, but there is no specific timeline yet," a company spokesman told Reuters. The drug would combine Ampio's experimental drug Zertane, which is being tested in a late-stage trial to treat premature ejaculation, with an erectile dysfunction drug similar to Pfizer Inc's (PFE.N) blockbuster medicine Viagra. There are currently no approved drugs in the United States to treat premature ejaculation and Ampio estimates up to 30 percent of males treated for premature ejaculation also suffer from erectile dysfunction. The biopharmaceutical company is also developing three other products to treat inflammation and eye damage due to diabetes. Shares of the company were up 11 percent at $5.68 on Monday on the Nasdaq, after soaring to … Continue reading →